Clinical Evidence: What the STEP Trials Actually Show
Key Difference Between Wegovy and Ozempic: Licensed Indications
The fundamental difference between Wegovy and Ozempic lies in their licensed indications, despite containing the same active ingredient, semaglutide. Wegovy is specifically licensed by the MHRA for weight management in adults with BMI ≥30, or BMI ≥27 with weight-related comorbidities. Ozempic, however, is exclusively licensed for type 2 diabetes treatment and cannot be legally promoted for weight loss in the UK. This distinction is crucial because prescribing medications outside their licensed indication raises safety and regulatory concerns.
When comparing the difference between Wegovy and Ozempic for weight management purposes, Wegovy represents the only evidence-based choice. The medication has undergone extensive clinical trials specifically for weight management, with comprehensive safety data in non-diabetic populations. Healthcare professionals can only legally prescribe Wegovy for weight management, making it the appropriate choice for patients seeking prescription weight loss support alongside a reduced-calorie diet and increased physical activity.
Wegovy Pricing and Value at EverydayMeds
Understanding the difference between Wegovy and Ozempic includes considering the cost of legitimate, licensed treatment. At EverydayMeds, Wegovy starts from £79.99 for the 0.25mg starter pen, with new customers using code FIRST40 at checkout. Our dose escalation bundles provide convenient progression through the mandatory titration schedule: the Intro Trio (0.25mg, 0.5mg, 1mg) costs £299.99, whilst the maintenance Ultimate Stability Trio (three 2.4mg pens) provides three months of supply for £649.99. All prices represent the final cost after discount codes are applied at checkout.
The difference between Wegovy and Ozempic pricing reflects the specialised nature of licensed weight management treatment. Our bundles offer convenience rather than just cost savings, ensuring uninterrupted supply during your weight management journey. Returning customers can use code DOSE25 for continued value, whilst our 24-hour express prescriber review service ensures rapid treatment initiation. Every order includes next-day temperature-controlled delivery, maintaining the cold-chain integrity essential for semaglutide effectiveness.
Clinical Evidence: STEP Trial Results for Wegovy
The difference between Wegovy and Ozempic becomes clear when examining clinical evidence for weight management. In the landmark STEP 1 trial, patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss over 68 weeks, compared to 2.4% with placebo (Wilding et al., NEJM, 2021). STEP 3 demonstrated even greater results of ~clinically studied weight loss when combined with intensive behavioural therapy, whilst STEP 5 showed sustained weight loss of ~15.2% maintained over two years.
These clinical trials specifically studied semaglutide as Wegovy in non-diabetic populations, establishing its safety and efficacy profile for weight management. The SELECT cardiovascular outcomes trial further demonstrated a 20% reduction in major cardiovascular events, highlighting additional health benefits beyond weight loss. This evidence base distinguishes Wegovy as the only semaglutide formulation with proven weight management efficacy in appropriate clinical populations.
How Wegovy Works: GLP-1 Receptor Mechanism
Understanding the difference between Wegovy and Ozempic requires knowledge of semaglutide's mechanism of action. Wegovy acts as a GLP-1 receptor agonist, mimicking the natural hormone glucagon-like peptide-1 that regulates appetite and food intake. This mechanism reduces appetite by affecting brain appetite centres, promotes feelings of fullness after smaller meals, and may reduce food cravings throughout the day. The once-weekly injection provides sustained GLP-1 receptor activation, supporting consistent appetite control between doses. Unlike rapid-acting appetite suppressants, Wegovy works gradually through physiological pathways that naturally regulate energy balance and satiety.
Ordering Process: From Assessment to Delivery
The difference between Wegovy and Ozempic extends to the ordering process for licensed treatment. At EverydayMeds, patients complete a comprehensive 3-minute online clinical assessment reviewed by qualified prescribers within our standard 3 working days, or 24 hours with express service. Our GPhC-registered pharmacy (#9012878) ensures every prescription meets MHRA requirements for safe weight management prescribing. Once approved, orders are dispatched via next-day cold-chain delivery, maintaining the 2-8°C temperature requirement essential for semaglutide stability. This process ensures patients receive authentic, licensed Wegovy rather than unlicensed alternatives, with full prescriber oversight throughout treatment.
Storage and Practical Considerations
The difference between Wegovy and Ozempic includes practical storage requirements that affect treatment convenience. Wegovy must be stored in the refrigerator at 2-8°C before first use, but offers a significant travel advantage of 6 weeks at room temperature below 30°C once removed from refrigeration. The FlexTouch pen design provides precise dose delivery through the mandatory escalation schedule: 0.25mg (weeks 1-4), 0.5mg (weeks 5-8), 1mg (weeks 9-12), 1.7mg (weeks 13-16), and 2.4mg maintenance from week 17. Each pen contains four doses for weekly injection, with clear dose indicators preventing administration errors. This storage flexibility and user-friendly design support treatment adherence throughout the weight management journey.
Regulatory Status: Why Licensed Indication Matters
The difference between Wegovy and Ozempic centres on regulatory approval and licensed indications in the UK. Wegovy received MHRA approval specifically for weight management following comprehensive clinical trials in appropriate populations, whilst Ozempic remains licensed exclusively for diabetes treatment. NICE TA875 recommends Wegovy for eligible patients within specialist weight management services, recognising its evidence-based efficacy. This regulatory framework ensures patients receive medications proven safe and effective for their specific condition, rather than off-label alternatives with uncertain safety profiles.
Understanding this difference between Wegovy and Ozempic protects patients from potentially inappropriate prescribing practices. Licensed medicines undergo rigorous safety monitoring, including Wegovy's Black Triangle ▼ status indicating additional MHRA surveillance. Our prescribers at EverydayMeds strictly adhere to licensed indications, ensuring every patient receives appropriate treatment aligned with current clinical guidelines and regulatory requirements for safe weight management support.
Making Your Choice: Professional Prescriber Support
The difference between Wegovy and Ozempic ultimately comes down to choosing licensed, evidence-based treatment for weight management. Our qualified prescribers assess each patient's individual circumstances, medical history, and treatment goals to ensure Wegovy represents an appropriate choice. Following clinical assessment, patients receive comprehensive treatment guidance including injection technique, side effect management, and lifestyle support recommendations. Remember, both effective weight management medications are available from EverydayMeds, though only Wegovy carries MHRA approval for weight management in non-diabetic patients. Start your weight management journey today with code FIRST40 for new customers, backed by our GPhC-registered pharmacy's commitment to safe, effective treatment delivery.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
